| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
|
| | 3-Pyridinecarboxamide, N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxy-1-pyrrolidinyl]-5-(4-isothiazolyl)- Basic information |
| | 3-Pyridinecarboxamide, N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxy-1-pyrrolidinyl]-5-(4-isothiazolyl)- Chemical Properties |
| Boiling point | 543.9±50.0 °C(Predicted) | | density | 1.519±0.06 g/cm3(Predicted) | | pka | 10.83±0.70(Predicted) |
| | 3-Pyridinecarboxamide, N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxy-1-pyrrolidinyl]-5-(4-isothiazolyl)- Usage And Synthesis |
| Uses | BCR-ABL-IN-3 is a potent and irreversible Bcr-Abl inhibitor with an IC50 of ≤100 nM for Ba/F3Bcr-AblT3151. BCR-ABL-IN-3 has anti-cancer activity[1]. | | in vivo | BCR-ABL-IN-3 (compound 7; 15 mg/kg; twice a day; for 19 days) has good antitumor effect in female NOD/SCID mice of 7-8 weeks weighing 21.8 g with Ba/F3Bcr-AblT3151 cells[1].
BCR-ABL-IN-3 (2 mg/kg for IV or 20mg/kg for PO) has a Cmax of 5485 ng/mL and an AUC of 5450 hng/mL for IV in male Sprague Dawley rats of 7-8 weeks old weighing 210 g[1].
| | IC 50 | Ba/F3Bcr-AblT3151: ≤100 nM (IC50) | | References | [1] Hanyi Wang, et al. (hetero)arylamide compound for inhibiting protein kinase activity. WO2018133826A1. |
| | 3-Pyridinecarboxamide, N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxy-1-pyrrolidinyl]-5-(4-isothiazolyl)- Preparation Products And Raw materials |
|